Intravenous injection of micafungin counteracts Candida albicans-induced aggravation of duodenal ulcers caused by cysteamine in rats

Digestive Diseases and Sciences

Volumn 53, Issue 9, 2008, Pages 2422-2428

  Nakamura, Tetsuya ^a   Yoshida, Masashi ^b   Kitagawa, Yuko ^a   Jin, Longxue ^a   Ishikawa, Hideki ^c   Kameyama, Kaori ^a   Wakabayashi, Go ^d   Tanabe, Minoru ^a   Kawachi, Shigeyuki ^a   Shinoda, Masahiro ^a   Saikawa, Yoshiro ^a   Wada, Norihito ^a   Kubota, Tetsuro ^a   Kumai, Koichiro ^a   Sano, Katsuko ^a   Kitajima, Masaki ^b  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^c Public Interest Foundation Corporation Life Extension Laboratory Attached Eiju General Hospital   (Japan)

^d IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Antifungal drug; Candida; Cysteamine; Infection; Micafungin; Perforation; Ulcer

Indexed keywords

MERCAPTAMINE; MICAFUNGIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFECT; DUODENUM ULCER; HISTOPATHOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SURVIVAL RATE;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; CYSTEAMINE; DUODENAL ULCER; ECHINOCANDINS; INJECTIONS, INTRAVENOUS; LIPOPROTEINS; MALE; RATS; RATS, WISTAR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 50249166673     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-007-0159-9     Document Type: Article

References (26)

1. T Nakamura M Yoshida 2006 Candida albicansaggravate the duodenal ulcer perforation after administering cysteamine in rats J Gastroenterol Hepatol 22 749 756
2. H Selyle S Szabo 1973 Experimental model for production of perforating duodenal ulcer by cysteamine in the rat Nature 244 458 459
3. S Szabo ES Reynolda SH Unger 1982 Structure-activity relations between alkyl nucleophilic chemicals causing duodenal ulcer and adrenocortical vecrosis J Pharmacol Exp Ther 223 68 76
4. Y Ikeda M Kitajima S Sohma 1982 Experimental studies on pathogenesis of duodenal ulcer in cysteamine induced rats (2nd report) Nippon Shokakibyo Gakkai Zasshi 79 2063 2070 in Japanese
5. S Szabo A Vincze Z Sandor 1998 Vascular approach to gastroduodenal ulceration. New studies with endothelins and VEGF Dig Dis Sci 43 40S 45S
6. Y Ikeda M Kitajima M Ueda S Sohma 1981 Studies on pathogenesis of cysteamine-induced duodenal ulcer in rats (1st report) Nippon Shokakibyo Gakkai Zasshi 78 2308 2315 in Japanese
7. Yoshida M, Szabo S, Khomenko T et al (1999) Endothelin-related increased vascular permeability is a common element in the early phase of duodenal ulceration. In: Terano A, Szabo S (eds) Further advances in gastrointestinal ulcer disease. Biomedis International, Tokyo, p 13-16
8. JP Gisbert J Legido I Garcia-Sanz JM Pajares 2004 Helicobacter pylori and perforated peptic ulcer prevalence of the infection and role of non-steroidal anti-inflammatory drugs Dig Liver Dis 36 2 116 120
9. M Sakaguchi H Oka K Amemoto 2002 Clinical investigation of perforated duodenal ulcer with special reference to the presence of Helicobacter pylori infection and rate of recurrence Nippon Shokakibyo Gakkai Zasshi 99 10 1197 1204 in Japanese
10. J Metzger S Styger C Sieber M Von Flue P Vogelbach F Harder 2001 Prevalence of Helicobacter pylori infection in peptic ulcer perforations Swiss Med Wkly 131 7-8 99 103 Feb 24
11. SC Lee CP Fung HY Chen 2002 Candida peritonitis due to peptic ulcer perforation: incidence rate, risk factors, prognosis and susceptibility to fluconazole and amphotericin B Diagn Microbiol Infect Dis 44 1 23 27
12. T Nakamura M Yoshida Y Otani 2006 Twelve years' progress in surgery for perforated gastric and duodenal ulcers: a retrospective study of indications for laparoscopic surgery, post-operative course, and the influence of Candida infection Aliment Pharmacol Ther 24 Suppl 4 297 302
13. M Zwolinska-Wcislo A Budak J Bogdal D Trojanowska J Stachura 2001 Fungal colonization of gastric mucosa and its clinical relevance Med Sci Monit 7 5 982 988
14. E Hagiwara N Nakamura 2000 Examination of bacteriology of the case of bleeding of perforating peptic ulcer J Abdom Emerg Med 20 4 505 512 in Japanese
15. S Tawara F Ikeda Y Morishita K Otomo N Teratani T Goto M Tomishima 2000 In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi Antimicrob. Agents Chemother 44 57 62
16. T Nakai K Hatano I Fumiaki M Seitaro 2002 Therapeutic effect of micafungin on oropharyngeal candidiasis in congenitally immunodeficient mice Jpn J Chemother 50 Suppl 1 48 53 in Japanese
17. T Hasebe S Harasawa T Miwa 1998 Factors affecting depth of gastric ulcers Tokai J Exp Clin Med 23 4 177 182 Oct
18. S Kusstatscher Z Sandor S Szabo A Seddon P Bohlen 1995 Different molecular forms of basic fibroblast growth factor (bFGF) accelerate duodenal ulcer healing in rats J Pharmacol Exp Ther 275 1 456 461
19. FM Muller O Kurzai J Hacker M Frosch F Muhlschlegel 2001 Effect of the growth medium on the in vitro antifungal activity of micafungin (FK-463) against clinical isolates of Candida dubliniensis J Antimicrob Chemother 48 5 713 715
20. SA Messer DJ Diekema L Boyken S Tendolkar RJ Hollis MA Pfaller 2006 Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp J Clin Microbiol 44 2 324 326
21. L Ostrosky-Zeichner D Kontoyiannis J Raffalli 2005 International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia Eur J Clin Microbiol Infect Dis 24 10 654 661
22. Y Yamato H Kaneko S Yamasaki 2002 Distribution and excretion after intravenous dosing of [14C] micafungin to rats Jpn J Chemother 50 Suppl 1 80 87 in Japanese
23. T Niwa Y Yokota A Tokunaga 2004 Tissue distribution after intravenous dosing of micafungin, an antifungal drug, to rats Biol Pharm Bull 27 1154 1156
24. S Towfigh C Chandler OJ Hines DW McFadden 2002 Outcomes from peptic ulcer surgery have not benefited from advances in medical therapy Am Surg 68 4 385 389
25. T Watanabe K Higuchi K Tominaga Y Fujiwara T Arakawa 2004 Peptic ulcer recurrence after successful eradication of Helicobacter pylori-clinical characteristics and management Nippon Rinsho 62 3 495 498 in Japanese, Mar
26. MM Rahman A Al Mamun MD Hossain MK Das 2005 Peptic ulcer perforation: management of high-risk cases by percutaneous abdominal drainage Trop Doct 35 1 30 31